Published online November 1, 2006
PEDIATRICS Vol. 118 No. 5 November 2006, pp. 2032-2037 (doi:10.1542/peds.2006-1422)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jackson, L. A.
Right arrow Articles by DeStefano, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackson, L. A.
Right arrow Articles by DeStefano, F.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Influenza
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Compliance With the Recommendations for 2 Doses of Trivalent Inactivated Influenza Vaccine in Children Less Than 9 Years of Age Receiving Influenza Vaccine for the First Time: A Vaccine Safety Datalink Study

Lisa A. Jackson, MD, MPHa, Kathleen M. Neuzil, MD, MPHb, James Baggs, PhDc, Robert L. Davis, MD, MPHc, Steve Black, MDd, Kristi M. Yamasaki, PharmDe, Ed Belongia, MD, MPHf, Kenneth M. Zangwill, MDg, John Mullooly, PhDh, James Nordin, MD, MPHi, S. Michael Marcy, MDj and Frank DeStefano, MD, MPHc

a Group Health Center for Health Studies, Seattle, Washington
b Program for Alternate Technologies in Health and Department of Medicine, University of Washington, Seattle, Washington
c Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia
d Kaiser Permanente Vaccine Study Center, Oakland, California
e Clinical Research Unit, Kaiser Permanente Colorado, Denver, Colorado
f Marshfield Clinic Research Foundation, Marshfield, Wisconsin
g Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, California
h Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon
i HealthPartners Research Foundation, Minneapolis, Minnesota
j Southern California Kaiser Permanente, Panorama City, California

OBJECTIVES. Children <9 years of age do not respond optimally to a first dose of trivalent inactivated influenza vaccine, and so 2 doses of trivalent inactivated influenza vaccine are recommended for children <9 years of age who are being vaccinated for the first time. We conducted a population-based retrospective cohort study to evaluate compliance with the 2-dose trivalent inactivated influenza vaccine recommendations.

POPULATION AND SETTING. We evaluated 125928 children 6 months through 8 years of age who were enrolled in health maintenance organizations in the United States participating in the Vaccine Safety Datalink project and who received their first dose of trivalent inactivated influenza vaccine in the 2001–2002, 2002–2003, or 2003–2004 influenza seasons.

RESULTS. Compliance with the 2 dose recommendations varied by age group and influenza season. Among children 6 to 23 months of age, the proportion of first-vaccinated children who received a second vaccination was 44% in 2001–2002, 54% in 2002–2003, and 29% in 2003–2004. Among children 2 to 8 years of age, the corresponding proportions were 15%, 24%, and 12%, respectively. In all seasons, compliance with the second vaccination was highest in children first vaccinated by mid-November.

CONCLUSIONS. The majority of children who received their first dose of trivalent inactivated influenza vaccine did not complete the 2-dose series. The recently expanded recommendation for universal vaccination of children 6 to 59 months of age and their household contacts will substantially increase the number of children targeted for a first influenza vaccination. Noncompliance with the 2-dose trivalent inactivated influenza vaccine series may be associated with suboptimal protection against infection, which may impact the magnitude of the direct and indirect benefits achieved by the vaccination program.

Key Words: influenza • influenza vaccine

Abbreviations: TIV—trivalent inactivated influenza vaccine • HAI—hemagglutination-inhibition • HMO—health maintenance organization

Accepted Jul 11, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?